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Chlamydia trachomatis is the major cause of infectious blindness and represents
the most common bacterial sexually transmitted infection worldwide. Considering the
potential side effects of antibiotic therapy and increasing threat of antibiotic resistance,
alternative therapeutic strategies are needed. Previous studies showed that water
filtered infrared A alone (wIRA) or in combination with visible light (wIRA/VIS) reduced
C. trachomatis infectivity. Furthermore, wIRA/VIS irradiation led to secretion of pro-
inflammatory cytokines similar to that observed upon C. trachomatis infection. We
confirmed the results of previous studies, namely that cytokine secretion (IL-6, IL-8, and
RANTES/CCL5) upon wIRA/VIS treatment, and the subsequent reduction of chlamydial
infectivity, are independent of the addition of cycloheximide, a host protein synthesis
inhibitor. Reproducible cytokine release upon irradiation indicated that cytokines might
be involved in the anti-chlamydial mechanism of wIRA/VIS. This hypothesis was tested
by inhibiting IL-6, IL-8, and RANTES secretion in C. trachomatis or mock-infected cells
by gene silencing or pharmaceutical inhibition. Celastrol, a substance derived from
Trypterygium wilfordii, used in traditional Chinese medicine and known for anti-cancer
and anti-inflammatory effects, was used for IL-6 and IL-8 inhibition, while Maraviroc, a
competitive CCR5 antagonist and anti-HIV drug, served as a RANTES/CCL5 inhibitor.
HeLa cell cytotoxicity and impact on chlamydial morphology, size and inclusion number
was evaluated upon increasing inhibitor concentration, and concentrations of 0.1 and
1 µM Celastrol and 10 and 20 µM Maraviroc were subsequently selected for irradiation
experiments. Celastrol at any concentration reduced chlamydial infectivity, an effect
only observed for 20 µM Maraviroc. Triple dose irradiation (24, 36, 40 hpi) significantly
reduced chlamydial infectivity regardless of IL-6, IL-8, or RANTES/CCL5 gene silencing,
Celastrol or Maraviroc treatment. Neither gene silencing nor pharmaceutical cytokine
inhibition provoked the chlamydial stress response. The anti-chlamydial effect of
wIRA/VIS is independent of cytokine inhibition under all conditions evaluated. Thus,
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factors other than host cell cytokines must be involved in the working mechanism of
wIRA/VIS. This study gives a first insight into the working mechanism of wIRA/VIS in
relation to an integral component of the host immune system and supports the potential
of wIRA/VIS as a promising new tool for treatment in trachoma.
Keywords: Chlamydia trachomatis, Celastrol, Maraviroc, wIRA irradiation, wIRA/VIS, cytokine gene silencing
INTRODUCTION
Chlamydia trachomatis represents both, the most common
bacterial sexually transmitted infection and the major cause of
infectious blindness, worldwide (Hu et al., 2013). The primary
frontline antibiotic used to treat ocular chlamydial infection
and prevent trachoma is azithromycin (Baneke, 2012), and
current WHO recommendations constitute mass treatment with
a single dose of azithromycin (WHO∗). Antibiotic treatment can
cause unwanted side-effects, is expensive and, particularly when
used improperly, may lead to antibiotic resistance. Although
resistance to azithromycin in C. trachomatis has not yet
been reported, resistance in Streptococcus pneumoniae, a major
cause of morbidity and mortality worldwide, increased after
azithromycin mass treatment (Ho et al., 2015). Experiences
from genital Chlamydia control programs suggest that early
antimicrobial treatment interferes with the development of
protective immune responses, leading to the “arrested immunity
hypothesis” (Brunham and Rekart, 2008). Moreover, a break in
the normal chlamydial developmental cycle can result in long-
term infection (Wyrick, 2010; Bavoil, 2014) and such infections
can cause a cascade of ongoing inflammatory-induced sequelae
resulting in scarring and fibrosis.
Chlamydiae are obligate intracellular bacteria with a complex
developmental cycle comprising the infectious elementary body
(EB) and the replicating reticulate body (RB). Under adverse
environmental conditions, developing chlamydiae may enter
a state referred to as persistence, more recently named the
chlamydial stress response or the aberrant body (AB) phenotype
(Wyrick, 2010; Bavoil, 2014; Leonard and Borel, 2014). This AB
chlamydial form is more resistant, or even refractory, to antibiotic
treatment in vitro and in animal models (Phillips-Campbell et al.,
2014; Borel et al., 2016). Since antibiotic side effects (cardiac
events/azithromycin – Lu et al., 2015), risk of development of
antibiotic resistance (Suchland et al., 2009; Sandoz and Rockey,
2010; Vanrompay et al., 2017) and insufficient compliance
during treatment (reviewed in Hammerschlag and Kohlhoff,
2012) represent serious drawbacks to current therapies, further
therapeutic strategies are needed.
Water-filtered infrared A (wIRA) is infrared radiation with
a spectrum of 780–1,400 nm, resulting from the light produced
by a halogen bulb passing through a water cuvette to exclude
wavelengths above 1,400 nm and through a black filter to
block visible light (VIS; Jung et al., 2012). Various clinical trials
have shown that wIRA alone and in combination with visible
light (wIRA/VIS) improves acute and chronic wound healing
processes (Hoffmann, 2007). Moreover, two studies showed
that wIRA/VIS treatment of abdominal wounds, before or after
surgery, not only improved wound healing and oxygen partial
pressure, but also reduced the rate of wound infections (Hartel
et al., 2006; Künzli et al., 2013).
Our initial studies (Marti et al., 2014) investigated whether
wIRA/VIS irradiation can reduce the number of chlamydial
inclusions, and therefore diminish recovery of both intra- and
extracellular infectious EBs, in cells infected with either human
(genital serovar E of C. trachomatis) or animal (C. pecorum
originating from a porcine abortion) chlamydial strains. A single
application of wIRA/VIS irradiation at 40 hours post-infection
(hpi) led to a significant (up to 70%) reduction of infectivity
in both strains of chlamydiae. Irradiation of host cells alone
(HeLa or Vero) neither affected cell viability nor induced
molecular markers of cytotoxicity (Marti et al., 2014). A triple
application of irradiation (24, 36, 40 hpi) during the course
of chlamydial infection further reduced chlamydial inclusion
frequency in HeLa cells without inducing the unfavorable
chlamydial persistence/chlamydial stress response. Quantitative
analysis of cytokine and chemokine levels in supernatants of cell
cultures subjected to triple irradiation revealed the release of
pro-inflammatory cytokines and chemokines upon irradiation or
infection alone, or in combination (Marti et al., 2014).
We carried out a follow-up study (Marti et al., 2015),
which investigated factors influencing the effect of wIRA/VIS on
acute chlamydial infection, namely the impact of temperature,
irradiation intensity, infectious dose and the efficacy of the VIS
component. Our findings demonstrated that thermal as well as
non-thermal effects of wIRA/VIS contribute to the inhibition
of acute chlamydial infection. Additionally, VIS enhanced the
inhibitory effect of wIRA on extracellular EBs, but the effect
of irradiation was not influenced by chlamydial infection dose.
The infectivity of mature chlamydial inclusions was significantly
reduced upon wIRA/VIS application at all evaluated irradiation
intensities, suggesting contribution of host cell factors to the anti-
chlamydial effect at the late stage of the chlamydial developmental
cycle (Marti et al., 2015). Experiments in permanent cell lines
(Marti et al., 2014, 2015) were performed in the presence of the
host cell protein synthesis inhibitor cycloheximide, whereas in an
additional follow-up study (Rahn et al., 2016) primary cell lines
without cycloheximide supplementation were used.
The abovementioned preliminary results encouraged our
further evaluation of wIRA/VIS as a potential non-chemical
treatment method for trachoma, the most common cause of
infectious blindness worldwide. Therefore, we employed an
in vitro model for ocular chlamydial infections using the ocular
C. trachomatis serovar B strain to infect human conjunctival
epithelial cells (HCjE) and evaluated the effects of wIRA/VIS
on non-infected ocular structures in two ex vivo eye models
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(Rahn et al., 2016). We demonstrated a significant wIRA/VIS-
dependent reduction of chlamydial infectivity in HCjE.
Unexpectedly, irradiation of HCjE prior to chlamydial infection
was sufficient to inhibit chlamydial infectivity, suggesting the
induction of a protective effect in wIRA/VIS-irradiated cells.
Considering potentially harmful effects, wIRA/VIS irradiation
did not reduce cell viability and post-treatment retinal damage
was not observed. Additionally, vitreal temperature during
wIRA/VIS irradiation did not markedly exceed physiological
eye temperatures, suggesting that hyperthermia-related lesions
are unlikely (Rahn et al., 2016). Therefore, wIRA/VIS has
shown considerable promise as a non-chemical method for
the treatment of ocular chlamydial infections, namely blinding
trachoma.
Though preliminary studies indicate that thermal as well as
non-thermal mechanisms are involved in the anti-chlamydial
effect of wIRA/VIS (Marti et al., 2015), our understanding of
the working mechanism of wIRA/VIS remains limited. In the
first investigation into this working mechanism, Marti et al.
(2014) detected increased cytokine and chemokine levels after
wIRA/VIS irradiation of HeLa cells, an effect congruent with
cytokine and chemokine release after C. trachomatis infection.
This suggests a potential anti-chlamydial effect of wIRA/VIS
based on immunological mimicry of chlamydial infections. In
this study, we therefore aimed to more specifically evaluate
the potential anti-chlamydial role of cytokines upon wIRA/VIS
irradiation of C. trachomatis-infected HeLa cells.
MATERIALS AND METHODS
Host Cells and Media
HeLa cells (Homo sapiens cervix adenocarcinoma, CCL-2
ATCC) were cultured at 37◦C with 5% CO2 in growth culture
medium for cell propagation. HeLa growth medium consisted of
Minimal Essential Medium with Earle’s salts (MEM; GIBCO, Life
Technologies, Carlsbad, CA, United States) supplemented with
4 mM GlutaMAX-I (GIBCO), 1% MEM Non-Essential Amino
Acids (MEM NEAA; 100x, GIBCO) and 10% fetal calf serum
(FCS; BioConcept, Allschwil, Switzerland). Medium used for
infections contained the same components as growth medium,
but was not supplemented with fetal calf serum. Cells were seeded
directly into wells or on round glass coverslips (13 mm diameter,
Thermo Fisher Scientific, Waltham, MA, United States) in 24-
well plates [Techno Plastic Products AG (TPP), Trasadingen,
Switzerland]. Infection experiments were performed 24 h post-
seeding or 59 h post-seeding (Figure 1).
Chlamydial Strain
The genital strain Chlamydia trachomatis Serovar E (E/UW-5/CX
kindly provided by Prof. R. V. Schoborg, Johnson City, TN,
United States) was used for in vitro infection experiments. The
isolate of the C. trachomatis strain was originally obtained from S.
P. Wang and C.-C. Kuo (University of Washington, Seattle, WA,
United States) and was propagated and harvested as described
previously (Leonard et al., 2015). Briefly, chlamydia stocks were
grown in HeLa cells (CCL-2, ATCC) at 37◦C in HeLa growth
medium supplemented with 1 µg/ml cycloheximide (CHX) in
an atmosphere of 5% CO2 for 46 h, harvested and stored at
−80◦C in SPG medium (218 mM sucrose; Sigma-Aldrich, St.
Louis, MO, United States), 3.76 mM KH2PO4 (Sigma-Aldrich),
7.1 mM K2HPO4 (Merck Eurolab AG, Dietlikon, Switzerland)
and 5 mM GlutaMAX-100 (GIBCO). For infection, HeLa cells
were seeded in 24-well plates and grown for 24 h at 37◦C, 5%
CO2. Infections were performed at a multiplicity of infection
(MOI) of 1 with subsequent centrifugation at 1,000 × g for 1 h
at 25◦C as described previously (Rahn et al., 2016).
wIRA/VIS Irradiation
Cultures were irradiated three times at 24, 36, and 40 hpi with
water-filtered infrared A combined with visible light (wIRA/VIS)
for 30 min using a wIRA radiator (hydrosun 750, Hydrosun
GmbH, Müllheim, Germany) at intensities ranging from 2340 to
3400 W/m2 (Figure 1). The resulting radiation spectrum ranges
from 380 nm up to 1,400 nm. The irradiation procedure, cooling
system and non-irradiated controls were the same as previously
described (Jung et al., 2010; Marti et al., 2014). Briefly, 24-
well plates were placed into a thermostat-controlled water bath
(SC100, Thermo Fisher Scientific) set to 37◦C. Non-irradiated
controls were placed on the same plates with suitable distance
from irradiated conditions to avoid any irradiation influence.
Irradiation was guided through optical fibers, reaching from the
wIRA radiator (emission source) to the surface of the appropriate
wells (irradiator point).
ELISA for IL-6, IL-8, and RANTES/CCL5
At 43 hpi, cell culture supernatants were collected, filtered
through 0.1 µm syringe filters (Whatman Anotop, Sigma-
Aldrich) and stored at −80◦C until further processing. Cytokine
levels were determined using human ELISA kits for IL-6 (ID:
KHC0061), IL-8 (ID: EH2IL8), and RANTES (ID: EHRNTS)
according to manufacturer’s instructions [InvitrogenTM (IL-6,
RANTES) Carlsbad, CA, United States, Thermo Fisher Scientific
(IL-8)]. Absorbance endpoint plate reading was performed on
an Epoch 2 Microplate Spectrophotometer (BioTek R©, Winooski,
VT, United States) at 450 nm wavelength, blank corrected
and evaluated by the four-parameter logistic ELISA curve
fitting provided by elisaanalysis.com. Cytokine concentrations
were calculated in Microsoft Excel (Microsoft, Redmont, WA,
United States) as average ± SD and expressed as percentage of
untreated controls. Since RANTES (also called CCL5) represents
a chemokine in the group of cytokines, it will be further referred
to as cytokine.
Study Design
Infection Experiments
The experiments were organized in four treatment groups:
(a) mock-infected and non-irradiated, (b) mock-infected and
irradiated, (c)C. trachomatis-infected and non-irradiated, and (d)
C. trachomatis-infected and irradiated. Centrifugation-assisted
infection of monolayers was performed as previously described
(Rahn et al., 2016), with replacement of the inoculum with
cycloheximide (CHX)-containing or CHX-free medium after
infection (time point 0) depending on the experimental setting,
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FIGURE 1 | Experimental design. (A) Experimental setting for pharmaceutical treatment: HeLa cells were seeded and cultured for 24 h before infection with MOI = 1
of C. trachomatis Serovar E. wIRA/VIS irradiation was performed at 24, 36, and 40 hpi, for 30 min application time of irradiation, ranging between 2340 and 3400
W/m2. Cell densities were 5 × 104 for pharmaceutical inhibition of cytokines and corresponding controls and 3 × 105 for cycloheximide supplementation and
2 × 105 for controls, respectively. After three additional hours of incubation (43 hpi), sampling for further analyses (including direct IFA, titration by sub-passage,
ELISA of supernatants) was performed. (B) Experimental setting for gene silencing: After seeding and culture of HeLa cells (density 2.5 × 104 cells/well), gene
silencing (or negative control siRNA transfection) was performed, followed by an additional incubation time of 35 h before infection with C. trachomatis Serovar E at
MOI = 1. Irradiation and sampling time points were the same as described in (A).
and the infected cells were incubated for 40 h, during which time
three applications of irradiation were administered (Figure 1).
Post-irradiation, an incubation for three additional hours was
applied and at 43 hpi, monolayers of all four groups were
either fixed with methanol for immunofluorescence assay (IFA,
on glass slides) or collected for titration by sub-passage as
previously described (Marti et al., 2014). IFA was performed
to label chlamydial LPS as previously described (Rahn et al.,
2016) and chlamydial inclusion morphology was assessed. To
determine mean inclusion size, 50 randomly selected inclusions
were examined per condition and area in µm2 was calculated
using BonTec measuring and archiving software (BonTec, Bonn,
Germany; Leonard et al., 2015). Number of inclusion forming
units (IFU) per mL was evaluated by sub-passage to determine
infectious chlamydial particles as described in detail elsewhere
(Rahn et al., 2016). IFU/mL was calculated and expressed
as percentage of the corresponding control. Unless stated
otherwise, experimental values were determined from duplicates,
three independent experiments were performed, and data was
expressed as the average ± standard deviation (SD) of three
experimental values. Measurements were tested for normal
distribution by Shapiro–Wilk test in R (R Core Team, 2016) and
statistical analysis was performed using Wilcoxon Rank Sum test
with p-values<0.05,<0.01 or<0.001 for significant differences.
Cycloheximide and Irradiation Experiments
(Figure 1A)
HeLa cells were seeded at a density of 2 × 105 cells/well
for conditions without CHX or 3 × 105 cells/well for CHX-
exposed conditions and incubated for 24 h before infection with
C. trachomatis Serovar E at a MOI of 1. After centrifugation,
infection media were replaced by cycloheximide-containing
(1 µg/ml, CHX) or cycloheximide-free (CHX-free) incubation
medium and further processed as described above.
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Silencing RNA (siRNA) for IL-6, IL-8, and
RANTES: Transfection Procedure,
Quantitative Real-Time PCR, and
Irradiation Experiments (Figure 1B)
Transfection Procedure
Transfection of HeLa cells was performed according to Ambion
manufacturer’s guidelines (Life technologies) in 24-well culture
plates using 6.25 nM siRNA and 2 µl Lipofectamine R© RNAiMAX
reagent for each siRNA (Thermo Fisher Scientific) under
normoxic conditions in OptiMEM I reduced serum medium
(Thermo Fisher Scientific).
A mixture of two different silencer select siRNA for each
cytokine (IL-6: ID: s7311, s7313; IL-8: ID: s7328, s7327; RANTES:
ID: s12575, s12577) with a final concentration of 12.5 nM siRNA
and 4 µl of Lipofectamine R© RNAiMAX reagent and one silencer R©
select negative control (#1 siRNA) with a final concentration of
6.25 nM siRNA and 2 µl Lipofectamine R© RNAiMAX reagent
and dissolved in OptiMEM to a total volume of 400 µl per
well was used. At the time of transfection, cell layers were
reaching a confluency of 20–30%. After an incubation time of
5 h, transfection reagents were replaced by usual HeLa growth
medium without CHX for the further incubation of cells.
Knockdown efficacy was confirmed by quantitative
polymerase chain reaction (qPCR) at 24, 48, 72, and 90 h
post-transfection in a preliminary experiment with two silenced
wells (duplicates) per time point and cytokine (see the Section
“Quantitative Real-Time PCR”). Transfection time point for
irradiation experiments was 24 h post-seeding and 35 h prior to
infection.
Quantitative Real-Time PCR
Total RNA was isolated using the RNeasy mini kit (ID: 74104,
Qiagen, Venlo, Netherlands) and RNA content was measured by
a NanoDrop Microvolume Spectrophotometer and Fluorometer
(NanoDrop Technologies, LLC, Wilmington, DE, United States).
150 ng of extracted RNA was reverse transcribed into cDNA
using the high-capacity cDNA reverse transcription kit (Applied
Biosystems, Foster City, CA, United States) according to
manufacturer’s guidelines (concentration of 15 ng/µl) on a
Biometra Trio Thermocycler (Analytik Jena, Jena, Germany).
PCR amplification was performed using the TaqManTM
Gene Expression Assays for IL-6 (Hs00174131_m1), IL-8
(CXCL8, Hs00174103_m1) and RANTES (Hs00982282_m1) and
the TaqMan R© Fast Universal PCR Master Mix [2x] (Applied
Biosystems) on a 7500- Fast ABI Thermocycler (Applied
Biosystems). Cycle protocol was set according to manufacturer’s
instructions.
Silenced samples were run in triplicates (RANTES) or
quadruplicates (IL-6, IL-8). Molecular-biology-grade water
(Thermo Fisher Scientific) served as no template controls
(NTC), which were run in duplicate, as were mismatch-silenced
controls. Relative quantification of IL-6, IL-8, and RANTES
mRNA expression was determined relative to the endogenous
control human Actin Beta [Human ACTB endogenous Control
4310881E (probe VIC, quencher TAMRA), Thermo Fisher
Scientific] using the 2−11CT method. Data was calculated
relative to the mismatch-silenced control mRNA levels using
Microsoft Excel (Microsoft).
Irradiation Experiments With Transfected Cells
HeLa cells were seeded at a density of 2.5 × 104 cells/well
and incubated for 24 h before transfection. Transfection was
performed as stated in “transfection procedure” and cells
were infected (or mock-infected) 35 h post-transfection. Non-
transfected cells (data not shown) and mismatch transfected cells
served as controls. After centrifugation, infection media were
replaced by CHX-free incubation medium and irradiation was
carried out as described in the Sections “wIRA/VIS Irradiation”
and “Infection Experiments.”
Pharmaceutical Inhibition of Cytokines:
Cell Viability Assays, Inhibitor
Concentration Curves, and Irradiation
Experiments (Figure 1A)
Cell densities for all experiments with pharmaceutical inhibition
of cytokines were 5 × 104 cells/well. Ethanol (100%) was
filtered through a 0.22 µm PES-membrane syringe filter (Techno
Plastic Products AG [TPP]) and used as solvent control or to
dilute pharmaceutic reagents. Based on the results of the cell
viability assays (see below), ethanol concentrations over 0.5%
were not used for further experiments. Celastrol 10 mg c0869
(Sigma-Aldrich), an inhibitor of IL-6 and IL-8, was dissolved
in 1 ml of 100% ethanol to a stock concentration of 10 mg/ml.
Maraviroc 10 mg 3756 (Tocris, Bristol, United Kingdom), a
selective CCR5 receptor antagonist (and therefore an inhibitor
of RANTES/CCL5), was dissolved in 1 ml of 100% ethanol to a
stock concentration of 10 mg/ml. Stocks were re-filtered through
0.22 µm PES-membrane syringe filters (TPP) and then stored
light-protected at−20◦C until further use.
Cell Viability Assays
Cell viability assays were run in triplicates: Cells were incubated
for 24 h before adding a range of concentrations of ethanol,
Maraviroc and Celastrol, depending on the experimental setting.
Cell viability under ethanol incubation was tested by mixing
100% ethanol in a 1:1 ratio with sterile phosphate-buffered
saline (PBS – GIBCO) and tested in HeLa growth medium at
concentrations of 10%, 5%, 1%, 0.5%, and 0.1%. The resulting
final concentrations of ethanol were 5%, 2.5%, 0.5%, 0.25%, and
0.05%. Maraviroc was tested at concentrations of 20 µM, 10 µM,
1 µM, and 0.1 µM and 0.103% ethanol in growth medium
served as the Maraviroc solvent control. Celastrol was tested at
concentrations of 25 µM, 2 µM, 1 µM and 0.1 µM and 0.113%
ethanol in growth medium served as the Celastrol solvent control.
10% Alamar blue dye (InvitrogenTM) was added to cell cultures
at 12, 24, 36, and 45 h (ethanol) or 48 h (Maraviroc/Celastrol)
after incubation. After 3 h of incubation at 37◦C, 2 × 200 µl,
Alamar blue dye/culture medium was transferred into 96 well
plates (generating two replicates from each well) and fluorescence
was monitored using a Synergy HT Reader 270230 (BioTek R©) at
530-nm excitation and 590-nm emission wavelength. Raw data
were analyzed as mean ± SD in Microsoft Excel (Microsoft) and
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expressed as percentage of controls. If not stated differently, heat
denatured cells served as positive controls.
Inhibitor Concentration Curves
To determine potential effects of the solvent (ethanol) and
pharmaceutic inhibitors on C. trachomatis, infections were
performed with supplemented media at the same concentrations
as in the cell viability assays in triplicates, using 0.113%
(Celastrol) or 0.103% (Maraviroc) ethanol-containing medium as
corresponding mock-exposed controls.
Briefly, C. trachomatis stocks were diluted in infection media
supplemented with the appropriate concentrations of ethanol,
Celastrol or Maraviroc, to MOI of 1 and centrifuged for 1 h at
25◦C and 1,000 × g (Rahn et al., 2016). After centrifugation,
infection media were replaced by incubation medium with
corresponding ethanol, Celastrol or Maraviroc concentrations.
Cells were incubated for an additional 43 h, then fixed with
methanol as described previously (Marti et al., 2014). Inclusion
size and morphology were analyzed as described above. Inclusion
numbers were analyzed by counting inclusion numbers in
30 randomly selected view fields at 200-fold magnification.
Mean ± SD for each concentration were calculated in Microsoft
Excel (Microsoft) and expressed as percentage of untreated
control (data not shown) or mock-exposed controls.
Irradiation Experiments
Celastrol concentrations of 1 µM and 0.1 µM, and Maraviroc
concentrations of 20 µM and 10 µM were chosen for irradiation
experiments, based on the results of the cell viability assays
and inhibitor concentration curves. Corresponding volumes of
100% ethanol were used as mock-exposed controls reaching
final ethanol concentrations of 0.045% (1 µM and 0.1 µM
Celastrol), 0.103% (20 µM Maraviroc) and 0.0515% (10 µM
Maraviroc). Infection media and incubation media (CHX-free)
were supplemented with the inhibitors or 100% ethanol and the
same infection-, irradiation- and sampling steps as in previous
irradiation experiments were performed (see above).
RESULTS
wIRA/VIS Reduces Chlamydial Infectivity
Independent of Cycloheximide (CHX) and
Reduces Chlamydial Inclusion Size
(Figure 2)
To rule out potential effects of CHX, an eukaryote protein
synthesis inhibitor, on the irradiation efficacy of wIRA/VIS,
CHX-containing and CHX-free conditions were compared.
Chlamydial infectivity after irradiation was significantly reduced,
independent of CHX-addition, resulting in remaining chlamydial
infectivity of 10.14% (±0.81%) in CHX-containing conditions (p-
value < 0.01) and 13.94% (±4.70%) in CHX-free conditions (p-
value < 0.01; Figures 2A,B). The absolute chlamydial loads were
significantly higher (p-value < 0.01) in the CHX-supplemented
conditions compared to the CHX-free ones. CHX-containing
controls reached 6.56 × 107 ± 1.60 × 107 IFU/ml whereas
the CHX-free conditions with 1.18 × 106 ± 2.61 × 105
IFU/ml contained about 50 times less chlamydia. wIRA/VIS
irradiated conditions with CHX (6.63 × 106 ± 1.43 × 106
IFU/ml) and without CHX (1.62 × 105 ± 4.67 × 104
IFU/ml) displayed the same significance level (p-value < 0.01).
Furthermore, irradiated inclusions were visibly smaller than
those in the corresponding controls, which was further analyzed
by comparing inclusion sizes of untreated controls with
irradiated samples (n = 9). Mean inclusion sizes of non-irradiated
inclusions (305.47 µm2, ± 135.35 µm2) differed significantly
from those of irradiated inclusions (238.59 µm2, ±111.00 µm2)
as visible in Figure 2C (CHX-free, p-value< 0.001).
Cytokine Secretion (IL-6, IL-8, RANTES)
Upon wIRA/VIS Treatment Is
Independent of CHX (Figure 3)
HeLa cell secretion of IL-6, IL-8, and RANTES into the
culture media was analyzed upon infection, irradiation, or
the combination of both, and compared to the mock-infected
FIGURE 2 | wIRA/VIS reduces chlamydial infectivity independent of cycloheximide (CHX) and reduces chlamydial inclusion size. According to Figure 1, irradiation
experiments were performed. Experiments were run either without (A) or with (B) cycloheximide (CHX) supplementation following chlamydial infection. Chlamydial
infectivity upon titration by sub-passage was determined as IFU/ml and is presented in the black bars as percentage of non-irradiated controls (empty bars).
(C) Demonstrates the reduction of chlamydial inclusion size upon wIRA/VIS irradiation (n = 9). Significance levels are marked with asterisks: ∗p < 0.05, ∗∗p < 0.01,
and ∗∗∗p < 0.001.
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FIGURE 3 | Cytokine secretion of IL-6, IL-8, and RANTES upon wIRA/VIS treatment is independent of CHX. After seeding, infection and irradiation without (A) or
with (B) cycloheximide (CHX) supplementation, supernatants were collected for IL-6, IL-8, and RANTES ELISA analysis at 43 hpi. IL-6, IL-8, and RANTES levels are
expressed according to the experimental groups as percentage of non-irradiated controls. Treatment groups include mock-infected and non-irradiated conditions
(controls, empty bars), mock-infected and irradiated (bright gray bars), C. trachomatis-infected and non-irradiated (dark gray bars) and C. trachomatis-infected and
irradiated (black bars) conditions.
non-irradiated control. In the absence of CHX (Figure 3A),
IL-6 levels of 128.50% (±26.91%) upon irradiation, 149.96%
(±30.98%) upon infection and 114.66% (±19.86%) upon the
combination of both were observed. Upon irradiation, IL-8
levels increased to 195.62% (±97.25%) but were decreased
upon C. trachomatis infection (95.46% ± 40.63%) and upon
infection and irradiation (74.35% ± 10.66%). RANTES
secretion was increased in all three experimental conditions
(118.27% ± 25.82% upon irradiation, 115.24% ± 28.53% upon
infection, 107.22%± 20.16% upon the combination of both).
In the presence of CHX (Figure 3B), IL-6 secretion
was increased upon irradiation (106.24% ± 5.86%),
infection (154.20%, ± 18.28%) or the combination of both
(140.70% ± 22.14%). IL-8 levels showed increases to 107.32%
(±23.19%) upon irradiation, 134.58% (±50.57%) upon infection
and 113.74% (±48.12%) upon the combination of both. And,
finally, RANTES levels increased to 118.66% (±12.83%) upon
irradiation alone, 125.47% (±20.23%) upon infection alone and
128.07% (±24.20%) after irradiation and infection.
Gene Silencing of IL-6, IL-8, and RANTES
Downregulates mRNA Levels of All
Targets Over a Time Period of 90 h
(Supplementary Figure S1)
Decreases in mRNA levels were confirmed over a maximum
time period of 90 h post-transfection to ensure that reduced
mRNA levels of IL-6, IL-8, and RANTES were reached over
the duration of the irradiation experiments. Mismatch negative
silencer controls were evaluated at the same time points and
set to 100% gene expression. Gene expression levels of IL-6
began decreasing by 24 h (61.08% ± 4.55%) and dropped to
32.50% of control (±17.28%) after 48 h, 24.96% (±6.39%) after
72 h and 27.80% (±0.30%) after 90 h. mRNA levels of IL-8
dropped to 10.83% (±5.85%) within 24 h and reached 37.89%
(±4.01%) of control after 48 h, 43.44% (±2.35%) after 72 h and
33.71% (±3.67%) after 90 h. RANTES mRNA dropped to 24.87%
(±12.46%) at 24 h, 8.67% (±1.35%) at 48 h, 7.71% (±1.43%) at
72 h and 23.90% (±10.89%) at 90 h post-transfection.
The Reduction of Chlamydial Infectivity
by wIRA/VIS Is Independent of IL-6, IL-8,
or RANTES Gene Silencing (Figure 4)
Mismatch controls and target silenced cells were infected and
irradiated as described above. Using sub-passage titer assays,
chlamydial infectivity was calculated and expressed as percent
of non-irradiated, mismatch silenced controls. Infection of IL-
6 silenced cells resulted in chlamydial infectivity of 100.48%
(±38.81%; p-value > 0.05) of the control. wIRA/VIS irradiation
at 24, 36, and 40 hpi resulted in a significant reduction of the
chlamydial infectivity to 9.36% (±5.44%) for controls and 13.85%
(±7.91%) in IL-6 gene silenced cells (p-values< 0.01; Figure 4A).
Infection of IL-8 silenced cells resulted in increased, but not
significant (p > 0.05) chlamydial loads of 142.61% (±36.79%).
wIRA/VIS treatment of infected cells reduced chlamydial
infectivity significantly to 9.36% (±5.44%) in controls and 17.04%
(±15.04%) in IL-8 silenced cells (p< 0.01; Figure 4B).
Infection of RANTES silenced cells resulted in chlamydial
loads of 62.36% (±32.71%), which was not statistically significant
compared to controls. Irradiation reduced chlamydial infectivity
significantly (p< 0.001) to 7.37% (±4.36%) in controls and 2.91%
(±2.91%) in RANTES silenced conditions (n = 5, Figure 4C).
Increasing Ethanol and Celastrol
Concentrations Decrease Cell Viability
While Maraviroc Concentrations up to
20 µM Have No Effect on Cell Viability
(Supplementary Figure S2)
Ethanol was employed as the diluent for Celastrol and Maraviroc
in this study. Five ethanol concentrations (0.05%, 0.25%, 0.5%,
2.5% and 5.0%) were analyzed for potential impact on host cell
viability at 12, 24, 36, and 45 h post-incubation, as measured
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FIGURE 4 | Gene silencing of IL-6, IL-8, and RANTES does not influence the
anti-chlamydial effect of wIRA/VIS. After seeding, gene silencing for IL-6 (A),
IL-8 (B), and RANTES (C), infection with C. trachomatis serovar E and
irradiation, monolayers were sampled for titration by sub-passage to evaluate
chlamydial infectivity. Chlamydial infectivity, as IFU/ml, was determined and
expressed as percentage of non-irradiated control samples. Chlamydial
infectivity was significantly decreased in all irradiated conditions, independent
of gene silencing. Figures show results of three independent experiments for
IL-6 and IL-8 silencing and five experiments for RANTES gene silencing.
Significance levels are marked with asterisks: ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001.
by Alamar blue assay. At all ethanol concentrations, decreased
cell viability, compared to the control, was present at 24 h post-
incubation. However, cell viability at 36 and 45 h post-incubation
was increased or slightly decreased at ethanol concentrations
up to 0.5%, compared to controls, while concentrations of
2.5% and 5% reduced cell viability at all evaluated time points
(Supplementary Figure S2A).
Ethanol concentrations in Celastrol and Maraviroc dilutions
reached 0.113% and 0.103%, respectively, and were reflected in
the diluent controls for each inhibitor. Celastrol reduced cell
viability at concentrations of 2 µM and 25 µM (Supplementary
Figure S2B). Measured decrease in cell viability by Alamar blue
assay was accompanied by the presence of increased numbers of
rounded, detaching and floating cells and reduced cell confluency
(data not shown). Therefore, Celastrol concentrations of 1 µM
and 0.1 µM were chosen for irradiation experiments.
Maraviroc, even at the high concentration of 20 µM and
the longest incubation time of 48 h post-incubation, did
not induce any change in cellular morphology (data not
shown) or cell viability, thus, concentrations of 10 µM and
20 µM Maraviroc were chosen for irradiation experiments
(Supplementary Figure S2C).
Celastrol Reduces C. trachomatis
Inclusion Number and Size, Whereas
Maraviroc Only Reduces Inclusion
Number (Figure 5)
As determined by IFA analysis of inclusion morphology, none
of the evaluated ethanol, Celastrol or Maraviroc concentrations
induced signs of persistence such as AB formation (data not
shown). At 43 hpi, inclusion sizes in controls were 376.05 µm2
(±30.93 µm2) and 0.1 µM Celastrol incubated inclusions were of
similar size, 353.86 µm2 (±30.61 µm2). A significant reduction
in inclusion size (241.79 µm2, ± 20.00 µm2) was observed at
a concentration of 1 µM Celastrol (p < 0.001, Figure 5A).
Inclusion numbers were significantly reduced at 1 µM Celastrol
incubation (62.10% ± 9.96%, p < 0.001), whereas no significant
difference was seen at a Celastrol concentration of 0.1 µM
(101.38%± 12.56%; Figure 5B).
None of the evaluated concentrations of Maraviroc led to a
significant reduction of inclusion size compared to the control
(Figure 5C). Inclusion numbers were significantly decreased at
10 µM Maraviroc treatment to 84.45% (±3.05%, p-value < 0.01)
and at 20 µM (7.97% [±0.69%], p-value < 0.001, Figure 5D).
No significant differences from the control were observed at
Maraviroc concentrations of 0.1 µM or 1 µM.
The Reduction of Chlamydial Infectivity
by wIRA/VIS Is Independent of
Pharmaceutical Cytokine Inhibition by
Celastrol or Maraviroc (Figure 6)
Infective chlamydial loads were determined by sub-passage titer
assays and were calculated and expressed as percentage of
the control. Utilizing inhibitor concentrations with minimal
negative impact on cell viability [as described in the Sections
“Inhibitor Concentration Curves” and “Increasing Ethanol
and Celastrol Concentrations Decrease Cell Viability While
Maraviroc Concentrations up to 20 µM Have no Effect on
Cell Viability (Supplementary Figure S2)”] and associated
with the observed inhibitor-dependent decreases in inclusion
numbers discussed above, Celastrol incubation alone reduced
chlamydial loads. Samples incubated with 0.1 µM Celastrol
showed reduced infectivity of 84.47% (±14.51%) of the control,
whereas 1 µM Celastrol resulted in a significant reduction
(p < 0.01) of chlamydial infectivity to 11.77% (±4.57%) of the
control. Irradiation of Chlamydia-infected cells with wIRA/VIS
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FIGURE 5 | Celastrol significantly reduces C. trachomatis inclusion number and size, whereas Maraviroc reduces the inclusion number. C. trachomatis infection and
supplementation with Celastrol (A,B) and Maraviroc (C,D) were performed in parallel. After 43 h of incubation, monolayers were fixed with methanol and
immunofluorescence stained. Inclusion sizes (A,C) and numbers (B,D) were analyzed by either measurement of inclusions or counting of inclusion numbers per
fields (200× magnification) relative to controls (ctrl). Significance levels are marked with asterisks: ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
further decreased chlamydial infectivity to 6.89% (±4.32%) for
the controls, 6.15% (±2.28%) at 0.1 µM Celastrol, and to 0.77%
(±0.39%) at a concentration of 1µM Celastrol. Statistical analysis
showed significant differences for the reduction of chlamydial
infectivity upon irradiation in all three tested conditions, with
p-values of< 0.01 (Figure 6A).
C. trachomatis-infected inclusions incubated with 1 µM
Celastrol were smaller than control inclusions (Figure 6B) and
irradiation reduced inclusion sizes independent of Celastrol
treatment (data not shown) as observed for control samples
(Figure 2C).
Maraviroc treatment resulted in chlamydial infectivity of
113.24% (±7.68%) at 10 µM and 84.70% (±31.18%) at 20 µM
concentrations, respectively, compared to the control. Irradiation
with wIRA/VIS reduced chlamydial infectivity significantly in
all evaluated conditions (p < 0.01): Remaining infectivity after
irradiation was 5.06% (±2.24%) in controls (n = 6 for controls),
5.57% (±4.53%) in 10 µM and 6.46% (±5.19%) in 20 µM
Maraviroc conditions (Figure 6C). Maraviroc incubation alone
did not influence chlamydial inclusion morphology (Figure 6D).
DISCUSSION
Triple irradiation with wIRA/VIS during the course of
C. trachomatis infection significantly reduces chlamydial
infectivity in HeLa cells, which is in accordance with previous
studies (Marti et al., 2014, 2015; Rahn et al., 2016). CHX, a host
protein synthesis inhibitor, is known to promote chlamydial
infection (Ripa, 1977; Wyrick, 2010), which was also confirmed
in our study [see the Section “wIRA/VIS Reduces Chlamydial
Infectivity Independent of Cycloheximide (CHX) and Reduces
Chlamydial Inclusion Size (Figure 2)”]. Comparison of CHX-
containing and CHX-free irradiated conditions revealed similar
effects of wIRA/VIS treatment compared to the corresponding
controls, indicating that wIRA/VIS irradiation is independent of
CHX in our in vitro model (Figure 2).
The secretion of pro-inflammatory cytokines in response
to wIRA/VIS irradiation alone was independent of CHX
incubation (Figure 3): in the presence or absence of CHX,
wIRA/VIS-dependent increase in secretion of IL-6, IL-8, or
RANTES was, although not statistically significant, consistently
observed. This was in accordance with previous results of
cytokine regulation under wIRA/VIS irradiation (Marti et al.,
2014). Dessus-Babus et al. (2000) and Leonard et al. (2017)
reported increased IL-6 secretion after chlamydial infection
under CHX-influence, which we could confirm after comparing
CHX-free and CHX-incubated conditions by t-test (data not
shown). IL-8 secretion, however, was previously shown to
decrease after CHX-treatment of Chlamydia-infected host cells
(Dessus-Babus et al., 2000), which was not confirmed in our
study.
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FIGURE 6 | The pharmaceutical inhibition of IL-6, IL-8, or RANTES does not abolish the anti-chlamydial effect of wIRA/VIS on C. trachomatis. After seeding,
infection, Celastrol (A,B) or Maraviroc (C,D) supplementation and irradiation, monolayers were either fixed with methanol for direct IFA analysis (B,D) or sampled for
titration by sub-passage to determine chlamydial infectivity (A,C). Chlamydial infectivity was calculated as IFU/ml and expressed as percentage of the non-irradiated
control (ctrl). Bars represent results of three independent experiments. For Maraviroc (C), the two investigated concentrations were tested in separate experimental
settings and results were summarized into one figure, resulting in n = 6 for the control (ctrl). Significance levels are marked with asterisks: ∗∗p-values < 0.01. To
assess potential morphological changes under pharmaceutical inhibition, direct IFA of monolayers was performed and analyzed with regards to inclusion morphology
and size. Celastrol 1 µM alone led to significantly smaller inclusions compared to controls (ctrl) (B), whereas Maraviroc did not alter inclusion morphology (D).
In this study, we did not report significantly increased levels
of IL-6, IL-8, or RANTES upon chlamydial infection (alone
or in combination with wIRA/VIS irradiation; Figure 3). The
induction of IL-6 after C. trachomatis infection (in CHX-free
conditions) has been observed by other authors (Rasmussen et al.,
1997; Dessus-Babus et al., 2000; Gervassi et al., 2004; Cheng
et al., 2008; Buckner et al., 2013). Similar results were obtained
in multiple studies regarding IL-8 secretion (Rasmussen et al.,
1997; Gervassi et al., 2004; Buchholz and Stephens, 2006; Cheng
et al., 2008; Buckner et al., 2013). Dessus-Babus et al. (2000) also
studied HeLa cells infected with C. trachomatis Serovar E and
found increased IL-8 levels in the absence of CHX only after 48
hpi (not at earlier time points), but polarized cells were used in
contrast to the non-polarized cells in our study. Even though
Buckner et al. (2013) observed increases of IL-6 and IL-8, they
did not reproduce the magnitude of up-regulation observed by
Rasmussen et al. (1997).
Increased RANTES levels after C. trachomatis infection was
detected in investigations of the genital tract of mice infected with
C. trachomatis (Maxion and Kelly, 2002). In contrast, Buckner
et al. (2013) found decreased levels of RANTES in primary
endocervical epithelial cells after infection with C. trachomatis
Serovar D at 72 hpi.
Regardless of CHX-dependent effects on cytokine responses
to chlamydial infection, the increased cytokine levels after
wIRA/VIS irradiation, even though not significant, were a
constant finding for all investigated cytokines, and resembled
the detected cytokine release pattern reported by Marti et al.
(2014). Considering that chlamydiae are a known trigger for
cytokine secretion, their amount may also have a direct influence
on cytokine secretion levels (Maxion and Kelly, 2002). Even
though all infection steps were performed with MOI = 1
in our experiments, wIRA/VIS irradiation led to reduced
chlamydial infectivity in the samples, which potentially influences
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the amount of secreted cytokines (Maxion and Kelly, 2002).
Therefore, a theoretical correction of cytokine levels according to
chlamydial infectivity was performed and resulted in significantly
increased levels for all investigated cytokines under infection
and irradiation treatment (data not shown). This supported our
hypothesis that pro-inflammatory cytokines might play a role in
wIRA/VIS-dependent anti-chlamydial effects.
Targeted cytokine suppression in HeLa cells was achieved
by respective gene silencing (Supplementary Figure S1). The
introduction of double-stranded RNAs into mammalian cells
can lead to type I interferon (IFN) reactions involving IFN-α
and -β (Matsumoto et al., 2004) and is known to evoke non-
specific toxic effects in host cells (e.g., resulting in cell death
or general shut-down of host cell protein synthesis) (Wadhwa
et al., 2004; Seok et al., 2018), even though the used siRNAs
in our study are considered to induce minimal side effects
(manufacturer’s manuals). Interferons such as IFN-γ and host
cell factors such as amino acid starvation or iron deprivation
are known inducers of the so-called chlamydial stress response
(Wyrick, 2010; Schoborg, 2011). In view of this, we qualitatively
evaluated chlamydial inclusions upon chlamydial infection of
target and mismatch control silenced HeLa cells, with regards
to potential inclusion size reduction such as seen under DAMP
influences (Leonard et al., 2015), or regarding morphological
features indicative of AB formation but neither effect was
observed.
Cytokine gene silencing did not have a significant effect
on chlamydial infectivity [see the Section “The Reduction of
Chlamydial Infectivity by wIRA/VIS Is Independent of IL-
6, IL-8, or RANTES Gene Silencing (Figure 4)”] or cell
viability (compared to mismatch silenced conditions). However,
wIRA/VIS irradiation following gene silencing led to a reduction
of chlamydial infectivity similar to that observed in irradiated
mismatch silenced and non-transfected controls (Figure 4).
This indicates that the wIRA/VIS anti-chlamydial effect is
not abolished when mRNA transcription of pro-inflammatory
cytokines such as IL-6, IL-8, and RANTES is suppressed.
Next, we investigated the effect of pharmaceutical cytokine
suppression on the wIRA/VIS-dependent anti-chlamydial effect
by using commercially available cytokine inhibitors. Celastrol
is a natural substance derived from Thunder of God Vine
(Tripterygiumwilfordii) and used in traditional Chinese medicine
(Kannaiyan et al., 2011; Venkatesha et al., 2016). Celastrol
has been demonstrated to promote broad anti-inflammatory
and anti-cancer effects (Kannaiyan et al., 2011; Venkatesha
et al., 2016). In our study, we used Celastrol as an inhibitor
for IL-6 and IL-8 secretion. In preliminary experiments,
potential negative effects of Celastrol on HeLa cells were
evaluated by performing cell viability assays (Supplementary
Figure S2). Celastrol concentrations of 2 µM or higher reduced
cell viability, therefore, 1 µM and 0.1 µM were chosen
for subsequent irradiation experiments. Chiang et al. (2014)
observed significantly reduced cell proliferation in prostate
cancer cell lines for 0.1 µM concentration of Celastrol and
were able to explain this finding by cell cycle inhibition and
induced apoptosis. Shrivastava et al. (2015) observed similar
findings in breast cancer cell lines at Celastrol concentrations
ranging from 0.5 to 25 µM. Celastrol concentrations of
1 µM and 0.1 µM are considered effective for IL-6 and
IL-8 inhibition according to one supplier’s manuals (Santa
Cruz, recommended concentrations for Celastrol as cytokine
inhibitor: IC50 for IL-6 inhibition = 80 nM, IC50 for IL-8 210
nM+).
First, we performed concentration curve analyses for Celastrol
to gain insight into the effect of this inhibitor on chlamydial
inclusion morphology, size and number (Figure 5). Morphology
features indicative of persistence were not observed, but
inclusion size and numbers were significantly reduced at 1 µM
Celastrol concentration, compared to the control, whereas
0.1 µM concentration did not significantly change inclusion
size or numbers. The addition of Celastrol decreased chlamydial
infectivity, as assessed by sub-passage. This contrasts the results
of cytokine inhibition by gene silencing, where inhibition of IL-6
or IL-8 gene silencing did not significantly influence chlamydial
infectivity. To our knowledge, no studies including Celastrol
application and C. trachomatis have been performed until now.
Infectivity upon wIRA/VIS irradiation was invariably reduced
in all evaluated groups. In conclusion, the anti-chlamydial effect
of wIRA/VIS is independent of IL-6, IL-8 and pharmaceutical
treatment with Celastrol (Figure 6).
Maraviroc is a competitive CCR5 inhibitor approved for
treating HIV/AIDS patients (Xu et al., 2014; Vangelista
and Vento, 2018). CCR5 receptors are expressed on many
inflammatory cells (e.g., T-cells, macrophages or dendritic cells)
and serve as an important entry and binding site for the human
immunodeficiency virus (Oliveira et al., 2014; Xu et al., 2014).
HeLa cells in vitro and cervical cancer samples ex vivo were
demonstrated to express CCR5 (Sales et al., 2014; Che et al.,
2016), though in ex vivo samples, CCR5 expression could be
linked to the presence of leukocytes in the neoplastic areas (Sales
et al., 2014). Natural ligands of CCR5 receptors include CCL3,
CCL4, and RANTES (CCL5) (Oliveira et al., 2014; Vangelista
and Vento, 2018) and Maraviroc has been shown to inhibit
cytokine/chemokine effects at the CCR5 receptor (Dorr et al.,
2005). In a preliminary experiment, Maraviroc concentrations
of up to 20 µM were evaluated for potential negative effects on
HeLa cells, which was ruled out (Supplementary Figure S2).
Dorr et al. (2005) did not observe any negative effects on
cell proliferation or cytotoxicity using Maraviroc concentrations
up to 10 µM in PBMC and PM-1 cells. Concentration curve
experiments evaluating inclusion morphology, size and number
did not reveal changes indicative of chlamydial stress response
or decreases in chlamydial inclusion size except for Maraviroc
concentrations of 10 and 20 µM, which significantly reduced
inclusion numbers compared to the control (Figure 5). To
the author’s knowledge, there are no data available describing
the interaction between Maraviroc and C. trachomatis or other
chlamydial species. Sakthivel et al. (2008) attenuated the CCL5-
CCR5 (RANTES-CCR5) axis by using anti-CCL5 antibodies in a
mouse model with C. muridarum and revealed higher chlamydial
loads in mice under anti-CCL5 treatment.
Maraviroc incubation of C. trachomatis infected HeLa cells
led to a mild, but not significant increase of chlamydial
infectivity at 10 µM and decrease at 20 µM. The reduction
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of chlamydial infectivity upon wIRA/VIS irradiation, however,
was consistently observed after blocking the CCR5 receptor by
Maraviroc (Figure 6). To conclude, the wIRA/VIS effect does not
depend on uninhibited RANTES/CCR5 function.
Multiple studies, conducted in different models of chlamydial
infection using wIRA alone or wIRA in combination with
VIS irradiation, demonstrate that wIRA and wIRA/VIS have a
stable and reproducible inhibitory effect on chlamydial infectivity
(Marti et al., 2014, 2015; Rahn et al., 2016). Initial in vitro animal
models using Vero cells and C. pecorum, as well as in vitro human
models using HeLa cells and C. trachomatis Serovar E (genital
model) or a combination of both, consistently demonstrated
wIRA/VIS-dependent reduction of chlamydial inclusions and/or
EBs (Marti et al., 2014, 2015). These previous experiments
illustrated that wIRA and wIRA/VIS effects are independent of
chlamydial strain or host cell line. Subsequently, primary cell lines
(HCjE) were used in combination with C. trachomatis Serovar
B to mimic an in vitro eye model, in which the same anti-
chlamydial effects could be induced. Furthermore, irradiation of
host cells (HCjE) prior to chlamydial infection led to a similar
reduction of chlamydial infectivity as observed in previous
studies, which indicates a wIRA-mediated impact on host cells
possibly triggering a defense mechanism against chlamydial
uptake (Rahn et al., 2016).
Al-Ahmad et al. (2013) were the first authors, who investigated
the combination of photodynamic therapy and wIRA/VIS
(antimicrobial photodynamic therapy [aPDT]). Excellent
antimicrobial effects of aPDT have been demonstrated in
multiple studies, leading to severe reductions of bacterial loads
in multiple bacterial species and even in biofilms (Al-Ahmad
et al., 2013, 2015, 2016; Karygianni et al., 2014). In another study,
blue light with an emission peak at 460 nm was sufficient to
severely reduce loads of Aggregatibacter actinomycetemcomitans,
a periodontal pathogen (Cieplik et al., 2014). As a potential
working mechanism, activation of endogenous photosensitizers
and resulting antimicrobial effects were suspected (Cieplik et al.,
2014). Since 460 nm is included in the wIRA/VIS spectrum,
activation of endogenous photosensitizers by particular
wavelengths might be involved in the working mechanism.
Wavelength-specific effects on cellular structures have been
suspected/reported by multiple authors, e.g., Karu et al. (2001)
reviewed in Hoffmann (2007). Cytochrome c oxidase has recently
been identified as a photo-acceptor for irradiation in the range
of visible and near-infrared radiation (Passarella and Karu, 2014)
and potential working mechanism of wIRA/VIS might involve
changes in redox potential, changes in biochemical activity,
production of reactive oxygen species and photodynamic
actions as suspected by Karu (1999). Nonetheless, no working
mechanism regarding antimicrobial effects of wIRA/VIS has
been identified until now.
A previous study investigated cytokines as potential host
cell factors being influenced by wIRA/VIS (Marti et al., 2014).
In this study, we were able to gain a targeted insight into
the host cellular immune response upon wIRA/VIS irradiation.
We demonstrated that the reduction of chlamydial infectivity
after wIRA/VIS irradiation is not abolished by pharmaceutical
inhibition or gene silencing of host cell cytokines (IL-6, IL-8,
and RANTES). Thus, factors other than host cell cytokine
production must be involved in the working mechanism of
wIRA/VIS.
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FIGURE S1 | Gene silencing of IL-6, IL-8, and RANTES leads to sufficient
reductions of mRNA levels over experimental time. HeLa cells were seeded,
incubated for 24 h and transfected with siRNA for IL-6, IL-8, and RANTES gene
silencing or mismatch siRNA. After an incubation of 5 h, media were replaced by
HeLa growth medium. Sampling of monolayers for RNA isolation, reverse
transcription and quantitative real time PCR was performed at 24, 48, 72, and
90 h post-transfection. Reduction of mRNA levels compared to
mismatch-transfected samples and endogenous controls (actin beta) was
evaluated by the 2−11CT method and mRNA levels are expressed as percentage
of mismatch controls. IL-6 and IL-8 samples were run in quadruplicates, RANTES
samples in triplicates of two replicate samples.
FIGURE S2 | Increasing ethanol and Celastrol concentrations lead to reduced cell
viability, whereas Maraviroc concentrations up to 20 µM did not reduce cell
viability. Cell viability assays were performed by seeding HeLa cells (5 × 104
cells/well) followed by 24 h of incubation and replacement of incubation media by
ethanol (A), Celastrol (B) or Maraviroc (C) supplemented media at indicated
concentrations. Cell viability was assessed at 12, 24, 36, and 45 h (ethanol) or
48 h (Celastrol and Maraviroc as represented by empty bars in Figures 2B,C).
Cell viability is expressed as percentage of non-treated HeLa cells (A – control) or
as percentage of ethanol-incubated HeLa cells (diluent-controls; B,C).
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